YHC1142

YHC1142 is a preclinical-stage pharmaceutical candidate developed by Yuhan Corporation for the treatment of obesity. It is designed as a long-acting triple agonist that simultaneously targets the glucagon-like peptide-1 (GLP-1) receptor, the gastric inhibitory polypeptide (GIP) receptor, and the glucagon receptor. By activating these three distinct pathways, YHC1142 aims to achieve superior weight loss through a multi-pronged approach: appetite suppression and improved insulin secretion (via GLP-1 and GIP) combined with increased energy expenditure and thermogenesis (via glucagon). This synergistic mechanism is intended to provide enhanced efficacy compared to single or dual agonist therapies. The asset is currently undergoing preclinical evaluation to establish its safety and pharmacological profile.